Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 21

Sort by

Sort Order Select

Journal Articles

Clinical Outcomes of 420 MDS Patients Treated with 5-Azacytidine: Evaluation of Overall Survival, Duration of Treatment and Rate of Discontinuation in a Real Life Study from the Italian MDS Registry of Fondazione Italiana Sindromi Mielodisplastiche (FISM)

Blood (2016) 128 (22): 4341.

https://doi.org/10.1182/blood.V128.22.4341.4341

Published: 2016

Journal Articles

Incidence of Severe (≤ 10g/dl) Chronic Anemia in Elderly Patients with Newly Diagnosed Chronic Myeloid Leukemia Treated with Imatinib and Role of Erythropoietin Therapy

Laura Cesini, MD, Ida Carmosino, Melissa Campanelli, MD, Massimo Breccia, MD, Maria Lucia De Luca, Gioia Colafigli, Matteo Molica, Fulvio Massaro, Federico Vozella, Daniela Diverio, PhD, Marco Mancini, MD, Giuliana Alimena, Roberto Latagliata, MD

Blood (2016) 128 (22): 1903.

https://doi.org/10.1182/blood.V128.22.1903.1903

Published: 2016

Journal Articles

Erythropoietin therapy after allogeneic hematopoietic cell transplantation: a prospective, randomized trial

Aurélie Jaspers, Frédéric Baron, Évelyne Willems, Laurence Seidel, Kaoutar Hafraoui, Gaetan Vanstraelen, Christophe Bonnet, Yves Beguin

Blood (2014) 124 (1): 33–41.

https://doi.org/10.1182/blood-2014-01-546333

Published: 2014

Includes: Supplemental data

Journal Articles

Retrospective Review of Erythropoietin Therapy Versus Supportive Care in Newborns with Hereditary Spherocytosis (HS): Difficulties Implementing Trial Results Into Clinical Practice

Jacqueline F. Morrison, Ellis J. Neufeld, MD, PhD, Rachael F. Grace, MD

Blood (2011) 118 (21): 2066.

https://doi.org/10.1182/blood.V118.21.2066.2066

Published: 2011

Journal Articles

Minor Erythroid Response and Decreased WT1 Expression After Proteasome Inhibition by Bortezomib in Myelodysplastic Syndromes (GIMEMA MDS0104 Phase II Trial).

Massimo Breccia, MD, Roberto Latagliata, MD, Laura Cannella, MD, Ida Carmosino, MD, Enrico Gottardi, Daniela Cilloni, MD, Marco Vignetti, MD, Michelina Santopietro, MD, Marco Mancini, MD, Giuliana Alimena, MD

Blood (2009) 114 (22): 1777.

https://doi.org/10.1182/blood.V114.22.1777.1777

Published: 2009

Journal Articles

Intravenous Iron Sucrose for Children with Iron Deficiency and/or Gastrointestinal Hemorrhage.

Katherine Hall, BS, Shelley E. Crary, MD, MSCS

Blood (2009) 114 (22): 2006.

https://doi.org/10.1182/blood.V114.22.2006.2006

Published: 2009

Journal Articles

Chronic Granulomatous Disease and Mcleod Syndrome: Single Center Report of Four Cases.

Nizar Mahlaoui, MS, MSc, Marie-Dominique Dumont, MD, Thierry Peyrard, Pharm, D, Stephane Blanche, MD, PhD, Alain Fischer, MD, PhD

Blood (2009) 114 (22): 3595.

https://doi.org/10.1182/blood.V114.22.3595.3595

Published: 2009

Journal Articles

Darbepoetin-Alfa and I.V. Iron Administration after Autologous Hematopoietic Stem Cell Transplantation: A Prospective Randomized Multicenter Trial

Yves Beguin, Johan Maertens, Bernard De Prijck, Rik Schots, MD, Pascale Frere, Christophe Bonnet, Kaoutar Hafraoui, Evelyne Willems, Gaetan Vanstraelen, Marie Lejeune, Koen Theunissen, Georges Fillet, Frederic Baron

Blood (2008) 112 (11): 54.

https://doi.org/10.1182/blood.V112.11.54.54

Published: 2008

Journal Articles

Mesenchymal Stromal Cells Genetically Engineered To Overexpress Insulin-Like Growth Factor-1 Provide Paracrine Support for Cell-Based Erythropoietin Therapy of Chronic Renal Failure-Induced Anemia.

Terrence Kucic, BSc, Ian B. Copland, Ph.D., Jessica Cuerquis, B.Sc., Daniel L. Coutu, M.Sc., Lorraine E. Chalifour, Ph.D., Raymonde F. Gagnon, MD, FRCPC, Jacques Galipeau, MD, FRCPC

Blood (2007) 110 (11): 2598.

https://doi.org/10.1182/blood.V110.11.2598.2598

Published: 2007

Journal Articles

Erythropoietin Therapy Does Not Benefit Transfusion-Dependent Primary Myelofibrosis Patients and Treatment Response Is Infrequent with a Baseline Hemoglobin Level ≥ 10 g/dL.

Jocelin Huang, MD, Terra L. Lasho, MT(ASCP), Chin Yang Li, MD, Animesh D. Pardanani, MD, PhD, Ruben A. Mesa, MD, Ayalew Tefferi, MD

Blood (2007) 110 (11): 3555.

https://doi.org/10.1182/blood.V110.11.3555.3555

Published: 2007

Journal Articles

Treatment of Myelodysplastic Syndrome with Azacitidine and Erythropoietin .

Sewanti Limaye, MD, Jay Lipshitz, MD, Renuka Dulala, MD, Dilip Patel, MD

Blood (2007) 110 (11): 4627.

https://doi.org/10.1182/blood.V110.11.4627.4627

Published: 2007

Journal Articles

Erythropoietin Therapy and Venous Thromboembolic Events in Patients with Multiple Myeloma Receiving Chemotherapy with or without Thalidomide.

Maurizio Zangari, Federica Cavallo, Keshava Prasad, Louis Fink, Sharon Coon, Bart Barlogie, Guido Tricot

Blood (2006) 108 (11): 3572.

https://doi.org/10.1182/blood.V108.11.3572.3572

Published: 2006

Journal Articles

Unexpected Response to Erythropoietin Therapy in Intermediate-Low IPSS Myelodysplastic Syndromes.

M. Kwon, MD, M. Ballesteros, MD, I. Perez, MD, V. Echeverria, MD, M. Calderon, MD, N. Patrignani, MD, A. Escudero, MD, Jose L. Diez-Martin, MD, PhD

Blood (2006) 108 (11): 4867.

https://doi.org/10.1182/blood.V108.11.4867.4867

Published: 2006

Journal Articles

Dasatinib (Sprycel™) Therapy for Patients with Systemic Mastocytosis.

Srdan Verstovsek, MD, PhD, Hagop Kantarjian, M.D., Jorge Cortes, M.D., Farhad Ravandi-Kashani, M.D., Gautam Borthakur, M.D., Claude Nicaise, M.D., Inga Sams, M.D., Francis Giles, M.D., Ayalew Tefferi, M.D.

Blood (2006) 108 (11): 3627.

https://doi.org/10.1182/blood.V108.11.3627.3627

Published: 2006

Journal Articles

Erythropoietic Agents and Venous Thromboembolic Events in Multiple Myeloma Patients Treated with Anthracycline Based Chemotherapy and Immunomodulators.

Rachid Baz, MD, Steven M. Fruchtman, M.D., Jerome B. Zeldis, M.D., Esteban Walker, Ph.D, Mohamad A. Hussein, M.D.

Blood (2006) 108 (11): 5119.

https://doi.org/10.1182/blood.V108.11.5119.5119

Published: 2006

Journal Articles

Transplantation from Matched Unrelated Donors (MUD) for Thalassemia and Other Congenital Red Cell Disorders.

Kathryn S. Leung, MD, Ingrid Kuehnle, MD, Stephen Gottschalk, MD, Catherine M. Bollard, MD, Dean A. Lee, MD, Helen E. Heslop, MD, Malcolm K. Brenner, MD, Robert A. Krance, MD

Blood (2005) 106 (11): 2746.

https://doi.org/10.1182/blood.V106.11.2746.2746

Published: 2005

Journal Articles

Hematocrit and Oxygen Dependence of Nitric Oxide Scavenging by Red Blood Cells.

Daniel B. Kim-Shapiro, PhD, Ivan Azarov, BS, Kris T. Huang, BS, Neil Hogg, PhD, Mark T. Gladwin, MD

Blood (2005) 106 (11): 205.

https://doi.org/10.1182/blood.V106.11.205.205

Published: 2005

Journal Articles

Clinical Trial of Paricalcitol in Myelodysplastic Syndrome.

H. Phillip Koeffler, M.D., James O’Kelly, Ph.D., Noune Aslanian, M.D., The Southern California Leukemia Group

Blood (2004) 104 (11): 4720.

https://doi.org/10.1182/blood.V104.11.4720.4720

Published: 2004

Journal Articles

Sustained Control of Hemolysis and Symptoms and Reduced Transfusion Requirements over a Period of 2 Years in Paroxysmal Nocturnal Hemoglobinuria (PNH) with Eculizumab Therapy.

Anita Hill, MD, Dupe Elebute, MD, Judith C. Marsh, MD, Stephen J. Richards, PhD, Bruce McNutt, MD, Beth E. Petro, BS, Russell P. Rother, PhD, Peter Hillmen, PhD

Blood (2004) 104 (11): 2823.

https://doi.org/10.1182/blood.V104.11.2823.2823

Published: 2004

Journal Articles

Head-to-Head Comparison of Epoetin Alfa (EPO) 40,000 U QW vs Darbepoetin Alfa (DARB) 200 μg Q2W in Anemic Cancer Patients Receiving Chemotherapy (CT): Final Results of a Planned Interim Analysis (IA).

Roger Waltzman, MD, Denise Williams, MD.

Blood (2004) 104 (11): 4233.

https://doi.org/10.1182/blood.V104.11.4233.4233

Published: 2004

NARROW

Clinical Outcomes of 420 MDS Patients Treated with 5-Azacytidine: Evaluation of Overall Survival, Duration of Treatment and Rate of Discontinuation in a Real Life Study from the Italian MDS Registry of Fondazione Italiana Sindromi Mielodisplastiche (FISM)

Incidence of Severe (≤ 10g/dl) Chronic Anemia in Elderly Patients with Newly Diagnosed Chronic Myeloid Leukemia Treated with Imatinib and Role of Erythropoietin Therapy

Erythropoietin therapy after allogeneic hematopoietic cell transplantation: a prospective, randomized trial

Retrospective Review of Erythropoietin Therapy Versus Supportive Care in Newborns with Hereditary Spherocytosis (HS): Difficulties Implementing Trial Results Into Clinical Practice

Minor Erythroid Response and Decreased WT1 Expression After Proteasome Inhibition by Bortezomib in Myelodysplastic Syndromes (GIMEMA MDS0104 Phase II Trial).

Intravenous Iron Sucrose for Children with Iron Deficiency and/or Gastrointestinal Hemorrhage.

Chronic Granulomatous Disease and Mcleod Syndrome: Single Center Report of Four Cases.

Darbepoetin-Alfa and I.V. Iron Administration after Autologous Hematopoietic Stem Cell Transplantation: A Prospective Randomized Multicenter Trial

Mesenchymal Stromal Cells Genetically Engineered To Overexpress Insulin-Like Growth Factor-1 Provide Paracrine Support for Cell-Based Erythropoietin Therapy of Chronic Renal Failure-Induced Anemia.

Erythropoietin Therapy Does Not Benefit Transfusion-Dependent Primary Myelofibrosis Patients and Treatment Response Is Infrequent with a Baseline Hemoglobin Level ≥ 10 g/dL.

Treatment of Myelodysplastic Syndrome with Azacitidine and Erythropoietin .

Erythropoietin Therapy and Venous Thromboembolic Events in Patients with Multiple Myeloma Receiving Chemotherapy with or without Thalidomide.

Unexpected Response to Erythropoietin Therapy in Intermediate-Low IPSS Myelodysplastic Syndromes.

Dasatinib (Sprycel™) Therapy for Patients with Systemic Mastocytosis.

Erythropoietic Agents and Venous Thromboembolic Events in Multiple Myeloma Patients Treated with Anthracycline Based Chemotherapy and Immunomodulators.

Transplantation from Matched Unrelated Donors (MUD) for Thalassemia and Other Congenital Red Cell Disorders.

Hematocrit and Oxygen Dependence of Nitric Oxide Scavenging by Red Blood Cells.

Clinical Trial of Paricalcitol in Myelodysplastic Syndrome.

Sustained Control of Hemolysis and Symptoms and Reduced Transfusion Requirements over a Period of 2 Years in Paroxysmal Nocturnal Hemoglobinuria (PNH) with Eculizumab Therapy.

Head-to-Head Comparison of Epoetin Alfa (EPO) 40,000 U QW vs Darbepoetin Alfa (DARB) 200 μg Q2W in Anemic Cancer Patients Receiving Chemotherapy (CT): Final Results of a Planned Interim Analysis (IA).

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only